Tumor destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumor responses
- 8 February 2008
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 57 (9) , 1291-1300
Abstract
Electrochemotherapy (ECT) is an effective local therapy of human cutaneous cancers but has no effect on distant untreated tumors. We addressed whether tumor-associated antigens released after ECT could induce an efficient systemic immunity when associated with an appropriate immunoadjuvant.Keywords
This publication has 32 references indexed in Scilit:
- Synergy between In situ Cryoablation and TLR9 Stimulation Results in a Highly Effective In vivo Dendritic Cell VaccineCancer Research, 2006
- Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma1Neuro-Oncology, 2006
- Caspase-dependent immunogenicity of doxorubicin-induced tumor cell deathJournal of Experimental Medicine, 2005
- Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administrationSeminars in Cancer Biology, 2003
- CpG-oligonucleotides for cancer immunotherapy review of the literature and potential applications in malignant gliomaFrontiers in Bioscience-Landmark, 2003
- Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognitionProceedings of the National Academy of Sciences, 2001
- Systemic Antitumor Effects of Electrochemotherapy Combined with Histoincompatible Cells Secreting Interleukin-2Journal of Immunotherapy, 1995
- Electrochemotherapy, a new antitumor treatment. First clinical phase I-II trialCancer, 1993
- Cell electropermeabilization: a new tool for biochemical and pharmacological studiesBiochimica et Biophysica Acta (BBA) - Reviews on Biomembranes, 1993
- Evolution of cell‐mediated antitumor immunity in mice bearing a syngeneic chemically induced tumor. Influence of tumor growth, surgical removal and treatment with irradiated tumor cellsInternational Journal of Cancer, 1972